BusinessRare Hematology Market to Represent a Value of over US$ 16,000 Million by the End of 2022: Transparency Market ResearchBy Nasdaq OMXNov 14, 2017, 8:14 AM UTC
BusinessUK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia ABy Nasdaq OMXOct 13, 2016, 8:01 PM UTC
BusinessBioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy ProgramBy Nasdaq OMXApr 20, 2016, 12:30 PM UTC
BusinessBioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia ABy Nasdaq OMXMar 24, 2016, 12:30 PM UTC
BusinessBioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia ABy Nasdaq OMXMar 1, 2016, 10:43 PM UTC
